Summary: Author Robert Toland of MicrodoseHQ highlights the promising results of MAPS’ first from MAPS’ first of two Phase 3 trials of MDMA-assisted therapy for PTSD and the decades-long endeavor to forge ahead with psychedelic science. “MAPS Public Benefit Corporation is establishing a new paradigm in drug research, development, and commercialization in which we center our efforts wholly on the beneficiaries of our healing modality rather than shareholders,” highlights Amy Emerson, CEO of MAPS Public Benefit Corporation (MAPS PBC). “This approach commits us to open science and open books as we research best practices for psychedelic-assisted therapy. Ultimately, any proceeds from our work will be reinvested to generate more research, more training, and more affordable options for treatment,” says Emerson.